1734 results about "Degenerative disease" patented technology

Methods and systems for predicting the onset and progression of neurodegenerative diseases using blood test data and machine learning models are disclosed. The method involves receiving blood test values for a target subject over a previous time period, extracting features from the blood test data, and applying a trained predictive model to compute a risk score indicating the probability of developing a neurodegenerative disease. The system includes a processor that executes code to perform the method and can be implemented as a standalone application, cloud-based service, or integrated with healthcare systems. The predictive models are trained using supervised learning on labeled data and can include statistical models or machine learning algorithms. The systems and methods enable early detection of neurodegenerative diseases, personalized risk prediction, and integration with existing healthcare infrastructure. By leveraging blood test data and machine learning techniques, patient outcomes may be improved.

The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.Accordingly, the present invention relates to compounds of formula (Id)whereinR1 is H and R2 is selected from one of the substituents (i) and (ii) below; orR1 is selected from one of the substituents (i) and (ii) below and R2 is H; orR1 and R2 are both represented by substituent (i) below; orR1 and R2 are both represented by substituent (ii) below; orR1 is substituent (i) and R2 is substituent (ii); orR1 is substituent (ii) and R2 is substituent (i);wherein * indicates the attachment point; andwherein the carbon atom at the attachment point on substituent (i) is in the S-configuration; or a pharmaceutically acceptable salt thereof.

The present disclosure provides methods of differentiating pluripotent stem cells, including induced pluripotent stem cells, into lineage-specific floor plate midbrain progenitor cells, determined dopaminergic neuronal progenitor cells, committed dopaminergic neuronal progenitor cells and / or dopaminergic neuronal cells. Also provided are compositions uses thereof, such as for treating neurodegenerative diseases and conditions, including Parkinson's disease, and articles of manufacture and kits for use thereof.

The invention discloses application and a preparation method of exosome EGF-FGF-EXO containing double growth factors, the exosome EGF-FGF-EXO is uniform in particle size, high in loading efficiency and good in biological activity, the double growth factors comprise an epidermal growth factor EGF and a fibroblast growth factor FGF, and the epidermal growth factor EGF and the fibroblast growth factor FGF are added into the exosome EGF-FGF. The preparation method of the exosome EGF-FGF-EXO comprises preparation of an induced pluripotent stem cell (iPSC) exosome and loading of EGF-FGF, a recombinant epidermal growth factor (EGF) and a fibroblast growth factor (FGF) are loaded on the exosome from iPS-clone 12c, and the exosome product which has high biological activity and is used for treating nervous system diseases of neuroinflammation is prepared. The invention develops a brand new technical path for treatment of nervous system diseases, and in the fields of epilepsy, neurodegenerative diseases, brain injury and the like, the life quality of patients can be improved and important theoretical basis and technical support can be provided for precise medical treatment of nervous system diseases by precisely regulating and controlling neuroinflammation.

The present invention relates to a fused tricyclic compound, and a preparation method therefor and a use thereof. The compound has a structure shown in a formula (I), has an SARM1 inhibition effect, and can be used for treating neurodegenerative diseases.

The present invention relates to the fields of therapy and drug delivery. More specifically, disclosed herein are therapeutic methods and pharmaceutical compositions for treating disorders of blood-tissue barrier-shielded organs that harbour substantive populations of post-mitotic neurons, such as the organs derived from neural tube that include the central nervous system and the eye. The disclosed methods and compositions involve localised administration into such organs of an effector component that targets an intracellular biological target, in combination with a saponin component that enhances effective uptake of the effector component into the cells and / or that enhances effective routing of the effector component inside the cells where the biological target is present. For example, the effector component can be an oligonucleotide therapeutic that is targeting a gene product associated with the disorder of the CNS and / or of the eye. Due to cellular uptake-stimulating and / or endosomal escape enhancing effects of the saponin component, the presented herein neuropharmaceutical and ophthalmic compositions for the localised administration into the CNS and / or into the eye, respectively, can be formulated with lower concentrations of the effector component and / or at lower volumes, which confers safety-benefits to the neurons and to the comfort of the patient.

The invention discloses a retina thickness prediction method and system based on a multi-modal image, and the method and system achieve the effective estimation of the retina thickness under a low-cost condition through feature alignment and fusion modeling, and improve the basic screening and follow-up visit capability. According to the invention, through fusion of the multi-mode retina image data, the structure and function information of the optic nerve can be more comprehensively obtained, and the prediction accuracy of the thickness of the retina nerve fiber layer (RNFL) is improved. The OCT high-resolution hierarchical structure and the wide-view texture features of the eye fundus image are combined, so that anatomy and pathological states of optic nerves can be truly restored. The method can be used as an auxiliary method for early screening and early warning of optic neurodegenerative diseases such as glaucoma, and provides support for low-cost and high-efficiency primary screening and clinical auxiliary decision making.

The present disclosure relates to RIPK2 inhibitors represented by structural formula (I') or (X"): The disclosure further relates to pharmaceutical composition comprising the RIPK2 inhibitors and methods of treatment of conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease and cancer.

The invention relates to an intervertebral disc degenerative change analysis system based on multi-dimensional information. The system comprises a data processing module, a modifiable factor processing module, a circular RNA data processing module, a biomarker processing module, an image processing module, a treatment information processing module, a diagnostic feature anchoring module, a model generation module and a change analysis module. Anchoring is carried out on circular RNA, biomarkers, treatment information and modifiable factors through image information to form an anchoring network, and a reliable and effective basis can be provided for disease course analysis through big data and a large number of research results, so that each doctor has a targeted expectation and understanding on the disease course of a patient in the diagnosis stage; the method has the advantages that an interventional therapy scheme can be arranged in advance or the condition of a patient can be observed in real time, research results can be collected and fed back in time through big data, the information utilization rate is increased, and an information dimension integration scheme for degenerative disease recognition is created, and the accuracy of recognition results is improved.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating Parkinson's disease and a preparation method thereof. The traditional Chinese medicine preparation for treating Parkinson's disease comprises the following raw materials in parts by weight: 20-30 parts of bischofia polycarpa, 17-25 parts of eucommia ulmoides, 12-16 parts of artemisia sphaerocephala, 10-15 parts of lycopodium clavatum, 8-13 parts of elm leaves, 7-14 parts of pericarpium citri reticulatae, 5-10 parts of semen cuscutae and 2-7 parts of liquorice. In the formula, monarch, minister, assistant and guide are reasonably matched, the curative effect is exact, and the effects of regulating qi and blood, nourishing liver, warming kidney, activating blood and dissipating blood stasis are achieved. The compound can effectively improve core symptoms of Parkinson's disease and delay disease progression, is expected to be further developed into clinical drugs for treatment of Parkinson's disease, and provides an innovative scheme for traditional Chinese medicine treatment of neurodegenerative diseases.

The invention provides application of an SARM1 enzyme activity inhibitor in treating neurodegenerative diseases or neurological diseases or symptoms. The invention particularly provides a compound as an SARM1 enzyme activity inhibitor and a pharmaceutical composition of the compound. # imgabs0 #

Provided are an aromatic L-amino acid decarboxylase (AADC) / glial cell line-derived neurotrophic factor (GDNF) polynucleotide, and a use thereof in treating Parkinson's disease. Specifically, provided are a method for and a use in treating neurodegenerative diseases (such as Parkinson's disease) by delivering AADC and a GDNF to specific areas of the brain by a gene delivery system using AAV as a vector.

A bioenergy generator to increase the life force of a biological system is provided. The bioenergy generator includes fine pieces of natural stone, fine pieces of natural sand, fine pieces of metal, water and a supporting material operable to hold the natural sand, the natural stone, the metal, and the water together. Uses of the bioenergy generator are also provided, in particular, to treat a muscular degenerative disease and to improve genetic mutations.

The invention provides an application of a pentacyclic triterpenoid compound targeting hydroxyl steroid 17-beta dehydrogenase 4. The pentacyclic triterpenoid compound can effectively relieve or treat central nervous system diseases (inflammatory diseases), including central nervous system degenerative diseases or chronic central inflammatory diseases. The pentacyclic triterpenoid compound can maintain the structural stability or activity of hydroxysteroid 17-beta dehydrogenase and maintain the stability or activity of peroxisome, thereby relieving or treating central nervous inflammation. The pentacyclic triterpenoid compound can target hydroxysteroid 17-beta dehydrogenase 4, inhibit neuroglial cell excessive activation related neuroinflammation, relieve neuron damage or death speed and improve a central nervous system cell metabolism microenvironment.

The present disclosure, in part, provide compounds of Formula (I) that are VPS34 inhibitors, compositions, and methods of use thereof, such as in methods of treating cancer, diabetes, inflammatory diseases, neurodegenerative disorders, cardiovascular disorders, autoimmune diseases and viral infections:

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

The invention relates to the technical field of nervous system dysfunction, in particular to a nerve regulation and control system for degenerative disease treatment based on multi-modal physiological feedback, which comprises a central processing unit, an optical radiation applicator, a mechanical vibration applicator, an integrated biological signal sensing array and a man-machine interaction module, cooperative stimulation is applied by using a multispectral light source and a broadband vibrator, and multi-dimensional physiological signals such as heart rate variability, myoelectricity, galvanic skin and the like are monitored in real time through a sensor array. A multi-parameter adaptive control algorithm built in the central processing unit can dynamically and intelligently adjust stimulation parameters based on the feedback signals to form an accurate personalized treatment closed loop. Meanwhile, the safety monitoring module based on the biological thermal model ensures the safety boundary of the treatment process. According to the invention, intelligent, self-adaptive and non-invasive treatment of nerve dysfunction is realized.

The invention provides a fluorescent probe for detecting hydroxyl radicals as well as a preparation method and application thereof, and the preparation method comprises the following steps: (S10) synthesizing a first intermediate compound by taking 2, 3, 3-trimethyl-3H-indoline and methyl iodide as raw materials; (S20) synthesizing a second intermediate compound by taking phosphorus trichloride, cyclohexanone and anhydrous dimethylformamide as raw materials; (S30) mixing and reacting the first intermediate compound and the second intermediate compound to synthesize a compound IR780; and (S40) synthesizing OH-probe on the basis of the IR780. The prepared OH-probe has extremely high sensitivity and excellent selectivity on hydroxyl radicals, can be effectively used for monitoring and mapping the level of the hydroxyl radicals, and can be applied to detection of atherosclerosis, obesity, cancers, neurodegenerative diseases, inflammatory diseases and other free radical related diseases. Wide development prospects and practical application values are realized.

This application relates generally to the field of Bone Morphogenetic Protein (BMP) antagonists (soluble ALK6 fusion proteins), compositions thereof, and methods for use in treating neurodegenerative diseases and / or demyelinating diseases.

Functional imaging, in particular functional ultrasound imaging, is becoming a powerful tool for early detection of disorders such as neurodegenerative diseases. The present disclosure proposes a reliable method for such early detection, by delivering a stimulus to the nervous system, performing a functional imaging of an area of interest of the nervous system activated by the stimulus to obtain a series of hemodynamic Doppler images of the vascular network in the area of interest, and computing, from the series of hemodynamic Doppler images, a hemodynamic response (22) to the stimulus. The shape of hemodynamic response may be used to detect health disorders.

The present invention relates to compounds of Formula (I) that target PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: (I) wherein R2, R3, R4, R5, X, Y1, Y2, A1, A2, A3 and A4, and any groups associated therewith, are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PMS2 activity is implicated.

The present invention provides the use of an SARM1 enzyme activity inhibitor in the treatment of neurodegenerative or neurological diseases or disorders. The present invention particularly provides a compound of formula (I) as an SARM1 enzyme activity inhibitor and a pharmaceutical composition thereof. # imgabs0 #

Provided herein are methods and compositions for treating a neurodegenerative disease (e.g., AD or PSP). The methods can include administering to the subject a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound.

Disclosed herein are small molecule compounds, compositions, formulations, and methods of modulating gpl30. Compounds, compositions, and formulations described herein are capable of modulating pro-inflammatory, fibrotic and / or regenerative responses. The disclosure also provides methods for treating or ameliorating disease, disorders and conditions associated with gp130 activity, particularly those associated with inflammatory and degenerative disorders, or combination thereof.

The present disclosure provides compositions and methods comprising chimeric antigen receptors (CARs) specific for amyloid beta (Aβ) and / or Tau. In certain embodiments, the CARs do not comprise an intracellular domain. Methods of treatment are also disclosed herein.

The invention discloses a preparation method and application of a novel bird nest alkane diterpenoid compound, and relates to the technical field of medicinal chemistry. The invention aims to solve the problems that chemical synthesis needs harsh conditions and the cost is difficult to control when diterpenoid compounds are obtained in the prior art, and a large amount of resources are wasted and new molecules are difficult to obtain under conventional fermentation conditions. The prepared bird nest alkane type diterpene has dual functions of promoting neurite growth and nourishing neurons, is expected to be developed into a neuroprotective agent, and is used for treating neurodegenerative diseases and peripheral nerve injury diseases; meanwhile, the problems that in the prior art, when the compounds are obtained, conditions needed by chemical synthesis are harsh, the cost is difficult to control, a large number of resources are wasted under conventional fermentation conditions, but new molecules are difficult to obtain, and production and smooth follow-up biological activity research are not facilitated are effectively solved. The invention provides the preparation method and the application of the novel bird nest alkane diterpenoid compound.

A method for identifying biomarkers indicative of neurodegeneration using a covariance neural network (VNN) includes providing a VNN trained on brain anatomical data primarily composed of healthy subjects, making the largest proportion of the population in the data. Brain anatomical data of a subject is provided as input, and, based on the input, the VNN generates a set of biomarkers and a brain health marker indicative of neurodegeneration of the subject.

The invention provides a cyclic peptide used for treating, improving or preventing nervous system injury of mammals or diseases or pains caused by the injury, neurodegenerative diseases, anxiety or epilepsy or used as a neuronal protective agent, a conjugate containing the cyclic peptide, a pharmaceutical composition containing the cyclic peptide or the conjugate and application of the cyclic peptide and the conjugate.

The invention provides a novel light-sensitive channel protein VR2.0 and application thereof. The photosensitive channel protein VR2.0 series provided by the invention has an obvious treatment effect in treatment of retina photoreceptor cell degenerative diseases. The novel light-sensitive channel protein has higher light sensitivity, fast dynamics and low side effect; under the same light stimulation condition, the response frequency is fast, and stable current signals can be kept under high frequency response. The application provides a better choice for developing photogenetic therapy for retina photoreceptor cell degenerative diseases, and has important application and popularization values.